TNFA
Q/C Technologies, Inc.5.20
+1.69+48.1%
Sep 24, 4:00:01 PM EDT
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.60MP/E (TTM)
-Basic EPS (TTM)
-202.00Dividend Yield
0%Recent Filings
8-K
8-K
Voss joins board, consulting deal
Q/C Technologies signed a 12-month consulting agreement with Chelsea Voss on January 16, 2026, paying $12,500 monthly plus 212,500 RSUs and options, while appointing her to the board. Voss, an OpenAI engineer behind GPT-4 and ChatGPT, will advise on acquisitions, tech analysis, and intros. Board gains AI firepower. Yet vesting ties to service.
8-K
Shkreli consulting deal signed
Q/C Technologies entered a 12-month consulting agreement on December 8, 2025, with Ocean Avenue Holdings LLC, affiliated with Martin Shkreli, for services like acquisition advice and expert introductions. Compensation includes $12,500 monthly ($150,000 annually), warrants for 212,500 shares at $5.097 (vesting quarterly, 5-year term, 4.99%/9.99% ownership cap), and 212,500 restricted shares (quarterly vesting). Shkreli bolsters advisory depth. Equity dilutes shareholders slightly.
10-Q
Q3 FY2025 results
Q/C Technologies posted Q3 operating loss of $1.8M, improved 2.0% y/y from $1.8M while R&D expenses fell 49.7% y/y to $356K on suspended pharma trials; net loss widened to $2.8M from $1.9M due to $1.1M hit from Series H derivative fair-value change (derived). Cash swelled to $6.9M (up sharply y/y) on $9.4M financing inflows including Series H close Sept 4 for $7M (cash), funding $14.1M tech license acquisition from LPU Holdings (indefinite-lived, $9.4M contingent liability). OCF used $5.9M YTD; no FCF as capex not disclosed. Preferred dividends dilute common EPS to $(2.50). Nasdaq compliance hangs in balance.
8-K
Stockholders approve equity plan boost
Q/C Technologies stockholders approved the Incentive Plan Amendment on November 14, 2025, boosting shares available under the 2021 Equity Incentive Plan by 1,375,000 to 1,400,000 total. This equips the company to attract talent amid recent financings. Shareholders also greenlit a potential 1-for-2 to 1-for-250 reverse split. Plan bolsters retention.
BTQ
BTQ Technologies Corp.
6.61+0.27
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
FMTOF
Femto Technologies Inc.
0.54-0.02
IONQ
IonQ, Inc.
49.67+3.60
QFIN
Qfin Holdings, Inc.
19.10-0.11
QNCX
Quince Therapeutics, Inc.
3.70-0.07
QNRX
Quoin Pharmaceuticals, Ltd.
11.72+1.57
QNTM
Quantum Biopharma Ltd.
8.65+0.90
QTTB
Q32 Bio Inc.
2.88-0.17
QUBT
Quantum Computing Inc.
11.27+0.36